EMA Application withdrawn: Sevsury (surufatinib) — Hutchmed Europe B.V.

View source ↗

Summary

The EMA withdrawn the application for Sevsury (surufatinib) by Hutchmed Europe B.V. for neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Sevsury (surufatinib)

Snippet

Status: Application withdrawn. Therapeutic area: Neuroendocrine Tumors. MAH: Hutchmed Europe B.V.